Lipid PL40
Version 1.b773474a · 2026-09-13
| CAS No. | Not available |
| Chemical Name | Lipid PL40 |
| Synonyms | Lipid-PL40, PL 40, PL-40, CAMP lipid PL40 |
| SMILES | CCCCCCCCC(CC)OC(=O)CCCCCCCOP(=O)(NCCCN1CCN(CCCNP(=O)(OCCCCCCCC(=O)OC(CC)CCCCCCCC)OCCCCCCCC(=O)OC(CC)CCCCCCCC)CC1)OCCCCCCCC(=O)OC(CC)CCCCCCCC |
| Formula | C86H170N4O14P2 |
| M.Wt | 1,546.27 |
| Purity | ELSD-HPLC>95% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Zhang Z, Ma B, Li B, et al. Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging. Cell Reports Medicine. 2025;6:102209. |
PL40 is a cardiolipin-mimic phosphoramide (CAMP) lipid developed for antibody-free, T-cell-favored mRNA delivery. The cited study reported approximately 100-fold higher luciferase expression than ALC-0315 LNP and MessengerMax in primary human T cells under a specific in vitro assay, more than 80% GFP-positive human T cells at tested doses of at least 0.5 micrograms per 100,000 cells, and spleen-favored expression after intravenous administration. PL40 LNPs carrying circular uPAR CAR mRNA were also evaluated in preclinical liver-fibrosis and collagen-induced-arthritis models. All formulation and performance information shown below is literature-derived study evidence, not a product specification or a guarantee of reproducible LNP performance.
Specifications shown are product-page values, not batch test results.
Read Instructions for Use →